Three years on, half the complete responders in a prostate trial are still disease-free

Metastatic prostate cancer treatments are expected to slow the disease, not clear it. Long-term data presented at the European Society for Medical Oncology Congress 2026 point somewhere more hopeful for an investigational immunotherapy called SYNC-T. In a phase 1 trial of 15 men, 80% were alive at 24 months, median survival had still not been reached at nearly 30 months of follow-up, and of the six men whose cancer disappeared completely, half remain disease-free between about 26 and 35 months later. The therapy takes cells from the patient's own tumour and uses them to rally the immune system. A larger phase 2a trial is now enrolling at 24 US cancer centres, with international sites to follow. It is early data, and the company says so — but durable, disease-free survival is not a phrase this disease hears often.

SDG 3 · Good health and well-being — Mechanism: tech innovation